Objective To retrospectively analyze the impact of the low oxygen inducible factor-prolyl hydroxylase inhibitor—Roxadustat on infection events in peritoneal dialysis(PD)patients.Methods Totally 126 patients receiving maintenance PD treatment at Peritoneal Dialysis Center,Department of Nephrology,Peking University International Hospital from August 2019 to August 2022 were selected and divided into recombinant human erythropoietin(rHuEPO)group(59 cases)and Roxadustat group(67 cases)according to treatment drugs.The clinical indexes such as hemoglobin(Hb),C-reactive protein,iron metabolism and the incidence of infection were compared between the two groups.Results 90 infection events occurred in 74 patients,with a total infection rate of 58.7％.There were 45 cases(50.0％)of peritoneal dialysis-related peritonitis,exit site of peritoneal dialysis catheter and(or)tunnel infection,35 cases(38.9％)of respiratory tract infection.According to the cumulative infection rate per 1000 patient months,the total cumulative infection rate of rHuEPO group and Roxadustat group was 31.1 times per 1000 patient months and 38.2 times per 1000 patient months,respectively,with no statistical significance between the two groups(P＞0.05).The rate of PD catheter-related infection(18.7 times per 1000 patient months vs.14.3 times per 1000 patient months,P=0.461)and respiratory tract infection(10.6 times per 1000 patient months vs.17.2 times per 1000 patient months,P=0.323)in the rHuEPO and Roxadustat group,and there were no significantly differences between the two groups.Cox proportional hazards regression analysis showed that there was no statistically difference in total risk of infection between the Roxadustat group and the rHuEPO group after adjusting for age and dialysis age(HR 1.07,95％CI 0.65-1.76).Kaplan-Meier curve analysis showed that there was no significant difference in the cumulative incidence of PD pathway-related infections between the Roxadustat group and the rHuEPO group(P=0.270).The total iron binding capacity and unsaturated iron binding capacity in Roxadustat group were higher than those in rHuEPO group,and the difference was statistically significant(P＜0.05).Conclusion Compared with rHuEPO,Roxadustat does not increase the risk of infection in PD patients during the treatment of anemia.
peritoneal dialysisanemiaRoxadustatrecombinant human erythropoietininfection
国家科技期刊平台
NSTL
万方数据
